Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome

  • Gynecologic Endocrinology and Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To evaluate the effects of letrozole and cabergoline in a rat model of ovarian hyperstimulation syndrome (OHSS).

Study design

In this prospective, controlled experimental study, the 28 female Wistar rats were divided into four subgroups (one non-stimulated control and three OHSS-positive groups: placebo, letrozole, and cabergoline). To induce OHSS, rats were injected with 10 IU of pregnant mare serum gonadotropin from day 29 to day 32 of life, followed by subcutaneous injection of 30 IU hCG on day 33. Letrozole rats received with a single dose of 0.1 mg/kg letrozole via oral gavage, on the hCG day. Cabergoline rats received with a single dose of 100 µg/kg cabergoline via oral gavage, on the hCG day. All animals were compared in terms of body weight, vascular permeability (VP), ovarian diameter, ovarian tissue VEGF expression (assessed via immunohistochemical staining), and blood pigment epithelium-derived growth factor (PEDF) levels.

Results

The OHSS-positive placebo group (group 2) exhibited the highest VP, ovarian diameter, extent of VEGF staining, and lowest PEDF level, as expected. No significant difference was evident between the letrozole and cabergoline groups in terms of any of body weight; VP; PEDF level; ovarian diameter; or the staining intensity of, or percentage staining for, VEGF in ovarian tissues.

Conclusions

Letrozole and cabergoline were equally effective to prevent OHSS, reducing the ovarian diameter, VP, and PEDF and VEGF levels to similar extents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Klemetti R, Sevon T, Gissler M, Hemminki M (2005) Complications of IVF and ovulation induction. Hum Reprod 20(12):3293–3300

    Article  PubMed  Google Scholar 

  2. Stewart JA, Hamilton PJ, Murdoch AP (1997) Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12(10):2167–2173

    Article  CAS  PubMed  Google Scholar 

  3. McClure N, Healy DL, Rogers PA et al (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235–236

    Article  CAS  PubMed  Google Scholar 

  4. Pietrowski D, Szabo L, Sator M et al (2012) Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 27:196–199

    Article  CAS  PubMed  Google Scholar 

  5. Carizza C, Abdelmassih V, Abdelmassih S et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751–755

    Article  CAS  PubMed  Google Scholar 

  6. Liu X, Chen HH, Zhang LW (2013) Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol 6(2):221–227

    PubMed  PubMed Central  Google Scholar 

  7. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY (2004) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 101(17):6605–6610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S (2007) Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 14(8):832–835

    Article  CAS  PubMed  Google Scholar 

  9. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, Shimizu T, Inoue H, Imaizumi T (2006) Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 71(3):222–226

    Article  CAS  PubMed  Google Scholar 

  10. Saylan A, Arioz DT, Koken T et al (2010) Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 89:692–699

    Article  CAS  PubMed  Google Scholar 

  11. Tong XM, Zhang SY, Song T et al (2008) Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl) 121:2434–2439

    CAS  Google Scholar 

  12. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC et al (2006) Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability with-out altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147:5400–5411

    Article  CAS  PubMed  Google Scholar 

  13. Alvarez C, Marti-Bonmati L, Novella-Maestre E et al (2007) Dopamine agonist capergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937

    Article  CAS  PubMed  Google Scholar 

  14. Quintana R, Kopcow L, Marconi G et al (2008) Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril 90:1511–1516

    Article  CAS  PubMed  Google Scholar 

  15. Hong T, Cheng S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237–251

    Article  CAS  PubMed  Google Scholar 

  16. Delvigne A (2009) Symposium: update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 19(1):8–13 (review)

    Article  PubMed  Google Scholar 

  17. Hong Y, Chen S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237–251 (review)

    Article  CAS  PubMed  Google Scholar 

  18. He Qiaohua, Liang Linlin, Zhang Cuilian, Li Hangsheng, Zhaojia Ge Lu, Wang Shihong Cui (2014) Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med 60(6):355–360

    Article  CAS  PubMed  Google Scholar 

  19. Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, Cheng D, Xiao ZN, Li J (2013) Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome. Beijing Da Xue Xue Bao 45(6):869–872

    CAS  PubMed  Google Scholar 

  20. Kumar P, Sait SF, Sharma A, Kumar M (2011) Ovarian hyperstimulation syndrome. J Hum Reprod Sci 4(2):70–75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A (2008) Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 14(4):321–333

    Article  CAS  PubMed  Google Scholar 

  22. Chuderland D, Hasky N, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Shalgi R (2013) A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF). Hum Reprod 28(6):1626–1634

    Article  CAS  PubMed  Google Scholar 

  23. Busso CE, Garcia-Velasco J, Gomez R et al (2009) Symposium: update on prediction and management of OHSS. Prevention of OHSS–dopamine agonists. Reprod Biomed Online 19:43–51

    Article  CAS  PubMed  Google Scholar 

  24. Amir H, Yaniv D, Hasson J, Amit A, Gordon D, Azem F (2015) Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. J Reprod Med 60(1–2):48–54

    PubMed  Google Scholar 

  25. Kasum M, Vrčić H, Stanić P, Ježek D, Orešković S, Beketić-Orešković L, Pekez M (2014) Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecol Endocrinol 5:1–5

    Google Scholar 

  26. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B (2011) Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 21(9):85

    Article  Google Scholar 

  27. Garcia-Velasco JA, Quea G, Piro M et al (2009) Letrozle administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 92:222–225

    Article  CAS  PubMed  Google Scholar 

  28. Ceyhan ST, Onguru O, Fidan U, Ide T, Yaman H, Kilic S, Baser I (2011) Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol 154(1):100–104

    Article  CAS  PubMed  Google Scholar 

  29. Ferrero H, García-Pascual CM, Morales C, Simón C, Gaytán F, Pellicer A, Gómez R (2014) Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril 102(5):1468–1476

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Sifa University Medicine School, Sanayi cad. No: 7 Bornova, Izmir, Turkey

    Nur Şahin, Mine Genç & Gülüzar Arzu Turan

  2. Department of Obstetrics and Gynecology, M.H. Tepecik Research and Education Hospital, Izmir, Turkey

    Nesin Apaydın & Emrah Töz

  3. Department of Pathology, Sifa University Medicine School, Izmir, Turkey

    Oya Nermin Sivrikoz

  4. Department of Biostatistics and Medical Informatics, Sifa University Medicine School, Izmir, Turkey

    Hakan Cengiz

  5. Department of Obstetrics and Gynecology, M.H. Manisa Public Hospital, Manisa, Turkey

    Fatma Eskicioğlu

Authors
  1. Nur Şahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nesin Apaydın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emrah Töz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oya Nermin Sivrikoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mine Genç
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gülüzar Arzu Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hakan Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fatma Eskicioğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nur Şahin.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Şahin, N., Apaydın, N., Töz, E. et al. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch Gynecol Obstet 293, 1101–1106 (2016). https://doi.org/10.1007/s00404-015-3987-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-015-3987-4

Keywords

Search

Navigation